Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...

Biocon aims to introduce generic versions of the obesity drug Wegovy in India and Canada by late 2026 or early 2027, ...

The global Biosimilars Market , valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

Biocon is set to launch generic versions of Wegovy in India and Canada, aiming for market entry by late 2026 or early 2027.

By Rishika Sadam HYDERABAD (Reuters) -Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters, ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters ...

India's pharma and healthcare sector saw 57 deals worth $1.30 billion in the quarter ending June. This reflects a drop ...

Biocon plans to introduce generic versions of the weight-loss drug Wegovy in India and Canada by 2027, according to CEO Siddharth Mittal.

State Bank of India (SBI), the largest lender in the country, has launched a share sale to institutional investors to raise ...

Fundraising through qualified institutional placements (QIPs) saw a revival in June after a tepid first five months of 2025, ...

Top largecap stocks that mutual funds bought in June included Asian Paints, Trent, Bajaj Finserv, Infosys, and Bharti Airtel, ...

M&M, Wipro, Tech Mahindra, Nestle, SBI and Infosys led the gainers of Nifty 50 pack. Lack of fresh triggers, mixed global ...